Literature DB >> 21719142

Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells.

Hiroyuki Tao1, Yusuke Mimura, Keisuke Aoe, Seiki Kobayashi, Hiromasa Yamamoto, Eisuke Matsuda, Kazunori Okabe, Tsuneo Matsumoto, Kazurou Sugi, Hiroshi Ueoka.   

Abstract

Expression of the transcription factor FOXP3 characterizes regulatory T cells (Tregs) that engage in the maintenance of immunological self-tolerance and immune homeostasis. Intra-tumoral accumulation of Tregs is associated with unfavorable prognosis in several kinds of cancers. Recently, expression of FOXP3 and its association with prognosis have also been shown in some cancer cells in clinical studies. For non-small cell lung cancer (NSCLC), however, prognostic significance of tumor FOXP3 expression and its relationship with Tregs remain unknown. FOXP3 expression in cancer cells and tumor-infiltrating lymphocytes was examined by immunohistochemical staining of surgical specimens from 87 patients with NSCLC. Prognostic values of the tumor-infiltrating Treg count and tumor FOXP3 expression status were evaluated retrospectively. FOXP3-positive cancer cells were observed in 27 of 87 (31.0%) patients. There was no significant relationship between Treg count and tumor FOXP3 status. Increased Treg counts were associated with worse overall and relapse-free survival whereas the influence of tumor FOXP3 status on survival was not significant. However, when FOXP3-positive cancer cells were present, the relationship between Treg accumulation and worse prognosis was attenuated. In contrast, patients without tumor FOXP3 expression and high Treg count had significantly worse overall and relapse-free survival (hazard ratio: 3.118 and 3.325, p=0.028 and 0.024, respectively) than other groups. These results suggest that tumor FOXP3 expression has a better prognostic potential in NSCLC and that in combination with tumor-infiltrating Treg count the absence of tumor FOXP3 allows the selection of high-risk patients.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21719142     DOI: 10.1016/j.lungcan.2011.06.002

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  102 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

Review 2.  The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome.

Authors:  Romain Remark; Christian Becker; Jorge E Gomez; Diane Damotte; Marie-Caroline Dieu-Nosjean; Catherine Sautès-Fridman; Wolf-Herman Fridman; Charles A Powell; Nasser K Altorki; Miriam Merad; Sacha Gnjatic
Journal:  Am J Respir Crit Care Med       Date:  2015-02-15       Impact factor: 21.405

Review 3.  The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications.

Authors:  Panagiota Economopoulou; Christos Perisanidis; Evaggelos I Giotakis; Amanda Psyrri
Journal:  Ann Transl Med       Date:  2016-05

4.  IPEX Syndrome, FOXP3 and Cancer.

Authors:  Runhua Liu; Silin Li; Wei-Hsiung Yang; Lizhong Wang
Journal:  J Syndr       Date:  2013-06

5.  Analysis of regulatory T cells frequency in peripheral blood and tumor tissues in papillary thyroid carcinoma with and without Hashimoto's thyroiditis.

Authors:  Y Liu; X Yun; M Gao; Y Yu; X Li
Journal:  Clin Transl Oncol       Date:  2014-11-12       Impact factor: 3.405

Review 6.  Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer.

Authors:  D E Meyers; P M Bryan; S Banerji; D G Morris
Journal:  Curr Oncol       Date:  2018-08-14       Impact factor: 3.677

7.  Identification of prognostic immunophenotypic features in cancer stromal cells of high-grade neuroendocrine carcinomas of the lung.

Authors:  Akiko Takahashi; Genichiro Ishii; Tomonari Kinoshita; Tatsuya Yoshida; Shigeki Umemura; Tomoyuki Hishida; Kiyotaka Yoh; Seiji Niho; Koichi Goto; Hironobu Ohmatsu; Yuichiro Ohe; Kanji Nagai; Atsushi Ochiai
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-07       Impact factor: 4.553

Review 8.  Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer.

Authors:  Julie R Brahmer; Drew M Pardoll
Journal:  Cancer Immunol Res       Date:  2013-07-22       Impact factor: 11.151

9.  Foxp3 expression in CD4+CD25+Foxp3+ regulatory T cells promotes development of colorectal cancer by inhibiting tumor immunity.

Authors:  Xiao-Wen Zhu; Hai-Zhen Zhu; You-Qing Zhu; Mao-Hui Feng; Jian Qi; Zhi-Fen Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18

10.  Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer.

Authors:  M P Petrova; I S Donev; M A Radanova; M I Eneva; E G Dimitrova; G N Valchev; V T Minchev; M S Taushanova; M V Boneva; T S Karanikolova; R B Gencheva; G A Zhbantov; A I Ivanova; C V Timcheva; B P Pavlov; V G Megdanova; B S Robev; N V Conev
Journal:  Clin Exp Immunol       Date:  2020-08-26       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.